Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer accused of funding anti- AstraZeneca info

12/06/2021 | 01:21am EST

US DRUGMAKER Pfizer, the world's dominant Covid vaccine maker, has been accused of funding educational presentations that said its UK rival AstraZeneca was ineffective and even dangerous for some members of the population.

A Channel 4 Dispatches investigation, due to be broadcast this week, said it had "uncovered evidence" that Pfizer funded a number of educational presentations that were delivered to health professionals across Canada about its mRNA vaccine.

Included in these presentations were slides that listed several disadvantages of the "viral vector" technology that is the basis for the AstraZeneca vaccine, the broadcaster said.

Delivered by speakers who had received funds from Pfizer, the slides said there is a risk of "chromosomal in- tegration and oncogenesis" with such vaccines, which suggests they might turn a healthy cell into a cancerous cell. They also claimed that the AstraZeneca vaccine cannot be used in immunocompromised people.

The claims made about the viral vector vaccine's disadvantages originated from a scientific paper written by a group of authors, one of whom had worked for several years on Pfizer jabs.

Channel 4 Dispatches did not say where it had found the evidence for these claims, and Pfizer denied it "sought to undermine others' scientific endeavours".

Professor Sir Andrew Pollard, part of the Oxford group that developed the AstraZeneca vaccine, said there was "absolutely zero evidence" that the vaccine "would or could" cause cancer, and that it had been given to millions of immunocompromised people and caused no harm.

(c) 2021 City A.M., source Newspaper

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.41% 8702 Delayed Quote.0.56%
PFIZER, INC. -1.53% 54.11 Delayed Quote.-8.37%
All news about ASTRAZENECA PLC
04:38aImfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tr..
AQ
03:49aAstraZeneca Says Liver Cancer Combination Therapy Improved Overall Survival in Late-Sta..
MT
02:59aAstraZeneca Says Imfinzi Combination Shows Unprecedented Liver-Cancer Survival Rate
DJ
01/18AstraZeneca's Liver Cancer Combo Extends Survival by Three Years in Late-Stage Study
MT
01/18AstraZeneca's Biliary Tract Cancer Combo Cuts Death Risk in Late-Stage Trial
MT
01/18Gates, Wellcome pledge $150 mln each to pandemic preparedness group
RE
01/18IMFINZI« (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line..
BU
01/18AstraZeneca Says Imfinzi Plus Chemotherapy Shows 20% Reduction in Risk of Death in Adva..
MT
01/18IMFINZI« (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanc..
BU
01/18ASTRAZENECA : Imfinzi plus tremelimumab demonstrated unprecedented survival in 1st-line un..
PU
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 100 M - -
Net income 2021 2 714 M - -
Net Debt 2021 24 811 M - -
P/E ratio 2021 54,4x
Yield 2021 2,37%
Capitalization 184 B 184 B -
EV / Sales 2021 5,78x
EV / Sales 2022 4,74x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 118,68 $
Average target price 138,63 $
Spread / Average Target 16,8%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC0.56%183 633
JOHNSON & JOHNSON-2.32%439 907
ROCHE HOLDING AG-3.75%322 066
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811
ELI LILLY AND COMPANY-10.55%223 992